{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T15:34:44Z","timestamp":1794065684177,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T00:00:00Z","timestamp":1542585600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12967-018-1694-1","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T14:36:01Z","timestamp":1542638161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["NLRC5: potential novel non-invasive biomarker for predicting and reflecting the progression of IgA nephritis"],"prefix":"10.1186","volume":"16","author":[{"given":"Yusa","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenggen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangli","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangcheng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,19]]},"reference":[{"key":"1694_CR1","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/ki.2012.280","volume":"82","author":"J Radhakrishnan","year":"2012","unstructured":"Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines-application to the individual patient. Kidney Int. 2012;82:840\u201356.","journal-title":"Kidney Int"},{"key":"1694_CR2","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368:2402\u201314.","journal-title":"N Engl J Med"},{"key":"1694_CR3","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.2169\/internalmedicine.45.1837","volume":"45","author":"Y Iwata","year":"2006","unstructured":"Iwata Y, Wada T, Uchiyama A, Miwa A, Nakaya I, Tohyama T, Yamada Y, Kurokawa T, Yoshida T, Ohta S, et al. Remission of IgA nephropathy after allogeneic peripheral blood stem cell transplantation followed by immunosuppression for acute lymphocytic leukemia. Intern Med. 2006;45:1291\u20135.","journal-title":"Intern Med"},{"key":"1694_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0046-8177(82)80221-9","volume":"13","author":"SM Lee","year":"1982","unstructured":"Lee SM, Rao VM, Franklin WA, Schiffer MS, Aronson AJ, Spargo BH, Katz AI. IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol. 1982;13:314\u201322.","journal-title":"Hum Pathol"},{"key":"1694_CR5","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/ki.2009.243","volume":"76","author":"DC Cattran","year":"2009","unstructured":"Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534\u201345.","journal-title":"Kidney Int"},{"key":"1694_CR6","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/ki.1997.171","volume":"51","author":"J Zwirner","year":"1997","unstructured":"Zwirner J, Burg M, Schulze M, Brunkhorst R, Gotze O, Koch KM, Floege J. Activated complement C3: a potentially novel predictor of progressive IgA nephropathy. Kidney Int. 1997;51:1257\u201364.","journal-title":"Kidney Int"},{"key":"1694_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000331453","volume":"35","author":"Y Shi","year":"2012","unstructured":"Shi Y, Chen W, Jalal D, Li Z, Chen W, Mao H, Yang Q, Johnson RJ, Yu X. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res. 2012;35:153\u201360.","journal-title":"Kidney Blood Press Res"},{"key":"1694_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.5414\/CN107813","volume":"80","author":"GY Cheng","year":"2013","unstructured":"Cheng GY, Liu DW, Zhang N, Tang L, Zhao ZZ, Liu ZS. Clinical and prognostic implications of serum uric acid levels on IgA nephropathy: a cohort study of 348 cases with a mean 5-year follow-up. Clin Nephrol. 2013;80:40\u20136.","journal-title":"Clin Nephrol"},{"key":"1694_CR9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.10331011","volume":"7","author":"S Lundberg","year":"2012","unstructured":"Lundberg S, Qureshi AR, Olivecrona S, Gunnarsson I, Jacobson SH, Larsson TE. FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol. 2012;7:727\u201334.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1694_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev.pathol.4.110807.092239","volume":"4","author":"G Chen","year":"2009","unstructured":"Chen G, Shaw MH, Kim YG, Nunez G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol. 2009;4:365\u201398.","journal-title":"Annu Rev Pathol"},{"key":"1694_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1146\/annurev-immunol-031210-101405","volume":"29","author":"BK Davis","year":"2011","unstructured":"Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol. 2011;29:707\u201335.","journal-title":"Annu Rev Immunol"},{"key":"1694_CR12","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.4049\/jimmunol.0903900","volume":"185","author":"S Benko","year":"2010","unstructured":"Benko S, Magalhaes JG, Philpott DJ, Girardin SE. NLRC5 limits the activation of inflammatory pathways. J Immunol. 2010;185:1681\u201391.","journal-title":"J Immunol"},{"key":"1694_CR13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/cr.2012.56","volume":"22","author":"Y Yao","year":"2012","unstructured":"Yao Y, Wang Y, Chen F, Huang Y, Zhu S, Leng Q, Wang H, Shi Y, Qian Y. NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens. Cell Res. 2012;22:836\u201347.","journal-title":"Cell Res"},{"key":"1694_CR14","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/cr.2012.53","volume":"22","author":"Y Tong","year":"2012","unstructured":"Tong Y, Cui J, Li Q, Zou J, Wang HY, Wang RF. Enhanced TLR-induced NF-kappaB signaling and type I interferon responses in NLRC5 deficient mice. Cell Res. 2012;22:822\u201335.","journal-title":"Cell Res"},{"key":"1694_CR15","doi-asserted-by":"publisher","first-page":"e00377","DOI":"10.1128\/JVI.00377-17","volume":"91","author":"CR Lupfer","year":"2017","unstructured":"Lupfer CR, Stokes KL, Kuriakose T, Kanneganti TD. Deficiency of the NOD-like receptor NLRC5 results in decreased CD8(+) T cell function and impaired viral clearance. J Virol. 2017;91:e00377.","journal-title":"J Virol"},{"issue":"3","key":"1694_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.kint.2018.02.031","volume":"94","author":"Q Li","year":"2018","unstructured":"Li Q, Wang Z, Zhang Y, Zhu J, Li L, Wang X, Cui X, Sun Y, Tang W, Gao C, et al. NLRC5 deficiency protects against acute kidney injury in mice by mediating carcinoembryonic antigen-related cell adhesion molecule 1 signaling. Kidney Int. 2018;94(3):551\u201366.","journal-title":"Kidney Int."},{"issue":"9","key":"1694_CR17","first-page":"853","volume":"1998","author":"RJ Wyatt","year":"1994","unstructured":"Wyatt RJ, Julian BA, Baehler RW, Stafford CC, McMorrow RG, Ferguson T, Jackson E, Woodford SY, Miller PM, Kritchevsky S. Epidemiology of IgA nephropathy in central and eastern Kentucky for the period 1975 through, Central Kentucky Region of the Southeastern United States IgA Nephropathy DATABANK Project. J Am Soc Nephrol. 1994;1998(9):853\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"1694_CR18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0022-5347(17)57082-2","volume":"120","author":"JB Dekernion","year":"1978","unstructured":"Dekernion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol. 1978;120:148\u201352.","journal-title":"J Urol"},{"key":"1694_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/ajkd.2000.8966","volume":"36","author":"G D\u2019Amico","year":"2000","unstructured":"D\u2019Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36:227\u201337.","journal-title":"Am J Kidney Dis"},{"key":"1694_CR20","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1681\/ASN.2010040355","volume":"22","author":"F Berthoux","year":"2011","unstructured":"Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011;22:752\u201361.","journal-title":"J Am Soc Nephrol"},{"key":"1694_CR21","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1681\/ASN.2007050526","volume":"18","author":"HN Reich","year":"2007","unstructured":"Reich HN, Troyanov S, Scholey JW, Cattran DC, Toronto Glomerulonephritis R. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18:3177\u201383.","journal-title":"J Am Soc Nephrol"},{"key":"1694_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/00005792-198105000-00004","volume":"60","author":"W Lloyd","year":"1981","unstructured":"Lloyd W, Schur PH. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore). 1981;60:208\u201317.","journal-title":"Medicine (Baltimore)"},{"key":"1694_CR23","first-page":"149","volume":"9","author":"S Satish","year":"2017","unstructured":"Satish S, Deka P, Shetty MS. A clinico-pathological study of lupus nephritis based on the International Society of Nephrology-Renal Pathology Society 2003 classification system. J Lab Phys. 2017;9:149\u201355.","journal-title":"J Lab Phys"},{"key":"1694_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/sj.ki.5002658","volume":"73","author":"E Heer de","year":"2008","unstructured":"de Heer E, Peters DJ. Innate immunity as a driving force in renal disease. Kidney Int. 2008;73:7\u20138.","journal-title":"Kidney Int"},{"key":"1694_CR25","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/cr.2012.83","volume":"22","author":"Y Zhao","year":"2012","unstructured":"Zhao Y, Shao F. NLRC5: a NOD-like receptor protein with many faces in immune regulation. Cell Res. 2012;22:1099\u2013101.","journal-title":"Cell Res"},{"key":"1694_CR26","doi-asserted-by":"publisher","first-page":"516","DOI":"10.4049\/jimmunol.1200064","volume":"189","author":"A Biswas","year":"2012","unstructured":"Biswas A, Meissner TB, Kawai T, Kobayashi KS. Cutting edge: impaired MHC class I expression in mice deficient for Nlrc5\/class I transactivator. J Immunol. 2012;189:516\u201320.","journal-title":"J Immunol"},{"key":"1694_CR27","doi-asserted-by":"publisher","first-page":"10554","DOI":"10.1038\/ncomms10554","volume":"7","author":"K Ludigs","year":"2016","unstructured":"Ludigs K, Jandus C, Utzschneider DT, Staehli F, Bessoles S, Dang AT, Rota G, Castro W, Zehn D, Vivier E, et al. NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions. Nat Commun. 2016;7:10554.","journal-title":"Nat Commun"},{"key":"1694_CR28","doi-asserted-by":"publisher","first-page":"5999","DOI":"10.1073\/pnas.1602069113","volume":"113","author":"S Yoshihama","year":"2016","unstructured":"Yoshihama S, Roszik J, Downs I, Meissner TB, Vijayan S, Chapuy B, Sidiq T, Shipp MA, Lizee GA, Kobayashi KS. NLRC5\/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci USA. 2016;113:5999\u20136004.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1694_CR29","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/j.1523-1755.2004.00486.x","volume":"65","author":"Y Xie","year":"2004","unstructured":"Xie Y, Chen X, Nishi S, Narita I, Gejyo F. Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney Int. 2004;65:1135\u201344.","journal-title":"Kidney Int"},{"key":"1694_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2215\/CJN.04700513","volume":"9","author":"NR Medjeral-Thomas","year":"2014","unstructured":"Medjeral-Thomas NR, O\u2019Shaughnessy MM, O\u2019Regan JA, Traynor C, Flanagan M, Wong L, Teoh CW, Awan A, Waldron M, Cairns T, et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol. 2014;9:46\u201353.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1694_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1471-2369-14-63","volume":"14","author":"Y Tan","year":"2013","unstructured":"Tan Y, Song D, Wu LH, Yu F, Zhao MH. Serum levels and renal deposition of C1q complement component and its antibodies reflect disease activity of lupus nephritis. BMC Nephrol. 2013;14:63.","journal-title":"BMC Nephrol"},{"key":"1694_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fimmu.2012.00052","volume":"3","author":"B Ghebrehiwet","year":"2012","unstructured":"Ghebrehiwet B, Hosszu KK, Valentino A, Peerschke EI. The C1q family of proteins: insights into the emerging non-traditional functions. Front Immunol. 2012;3:52.","journal-title":"Front Immunol"},{"key":"1694_CR33","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.4049\/jimmunol.173.5.3044","volume":"173","author":"AJ Nauta","year":"2004","unstructured":"Nauta AJ, Castellano G, Xu W, Woltman AM, Borrias MC, Daha MR, van Kooten C, Roos A. Opsonization with C1q and mannose-binding lectin targets apoptotic cells to dendritic cells. J Immunol. 2004;173:3044\u201350.","journal-title":"J Immunol"},{"key":"1694_CR34","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1096\/fj.201700511RR","volume":"32","author":"P Luan","year":"2018","unstructured":"Luan P, Zhuang J, Zou J, Li H, Shuai P, Xu X, Zhao Y, Kou W, Ji S, Peng A, et al. NLRC5 deficiency ameliorates diabetic nephropathy through alleviating inflammation. FASEB J. 2018;32:1070\u201384.","journal-title":"FASEB J"},{"key":"1694_CR35","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1053\/j.ajkd.2013.04.021","volume":"62","author":"J Lv","year":"2013","unstructured":"Lv J, Shi S, Xu D, Zhang H, Troyanov S, Cattran DC, Wang H. Evaluation of the Oxford Classification of IgA nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2013;62:891\u20139.","journal-title":"Am J Kidney Dis"},{"key":"1694_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.taap.2016.01.012","volume":"294","author":"X Liu","year":"2016","unstructured":"Liu X, Wu Y, Yang Y, Li W, Huang C, Meng X, Li J. Role of NLRC5 in progression and reversal of hepatic fibrosis. Toxicol Appl Pharmacol. 2016;294:43\u201353.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1694_CR37","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.biopha.2016.08.012","volume":"83","author":"HL Ma","year":"2016","unstructured":"Ma HL, Zhao XF, Chen GZ, Fang RH, Zhang FR. Silencing NLRC5 inhibits extracellular matrix expression in keloid fibroblasts via inhibition of transforming growth factor-beta1\/Smad signaling pathway. Biomed Pharmacother. 2016;83:1016\u201321.","journal-title":"Biomed Pharmacother"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-018-1694-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-018-1694-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-018-1694-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:22:36Z","timestamp":1574122956000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-018-1694-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,19]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1694"],"URL":"https:\/\/doi.org\/10.1186\/s12967-018-1694-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,19]]},"assertion":[{"value":"23 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"317"}}